Genetics of Parkinson disease

Handbook of Clinical Neurology

Volumn 147, Issue , 2018, Pages 211-227

  Domingo, Aloysius ^a   Klein, Christine ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

DJ1; GBA; genetic testing; genetics; LRRK2; PARKIN; Parkinson disease; PINK1; SNCA; VPS35

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PARK7 PROTEIN, HUMAN; PARKIN; PROTEIN DEGLYCASE DJ-1; PROTEIN KINASE; PTEN-INDUCED PUTATIVE KINASE; SNCA PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE; VESICULAR TRANSPORT PROTEIN; VPS35 PROTEIN, HUMAN;

GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; HUMAN; PARKINSON DISEASE;

ALPHA-SYNUCLEIN; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; PARKINSON DISEASE; PROTEIN DEGLYCASE DJ-1; PROTEIN KINASES; UBIQUITIN-PROTEIN LIGASES; VESICULAR TRANSPORT PROTEINS;

EID: 85042097433     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63233-3.00014-2     Document Type: Chapter

References (143)

1. Aasly, J.O., Vilariño-Güell, C., Dachsel, J.C., et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Mov Disord 25 (2010), 2156–2163.
2. Abeliovich, A., Schmitz, Y., Fariñas, I., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000), 239–352.
3. Ahn, T.B., Kim, S.Y., Kim, J.Y., et al. α-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 70 (2008), 43–49.
4. Albanese, A., Valente, E.M., Romito, L.M., et al. The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 64 (2005), 1958–1960.
5. Alcalay, R.N., Caccappolo, E., Mejia-Santanaet, H., et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling. Arch Neurol 67 (2010), 1116–1122.
6. Alcalay, R.N., Dinur, T., Quinn, T., et al. Comparison of parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 71 (2014), 752–757.
7. Anheim, M., Elbaz, A., Lesage, S., et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 78 (2012), 417–420.
8. Appel-Cresswell, S., Vilariño-Güell, C., Encarnacion, M., et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord 28 (2013), 811–813.
9. Bonifacino, J.S., Hurley, J.H., Retromer. Curr Opin Cell Biol 20 (2008), 427–436.
10. Bonifati, V., Genetics of Parkinson's disease – state of the art, 2013. Parkinsonism Relat Disord 20:Suppl 1 (2014), S23–S28.
11. Bonifati, V., Rizzu, P., van Baren, M.J., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003), 256–259.
12. Canet-Avilés, R.M., Wilson, M., Miller, D., et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 101 (2004), 9103–9108.
13. Chartier-Harlin, M.C., Dachsel, J., Vilariño-Güell, C., et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 89 (2011), 398–406.
14. Chen, Y., Dorn, G.W., PINK1-phosphorylated Mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 340 (2013), 471–475.
15. Choi, J.M., Soo Woo, M., Ma, H., et al. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 9 (2008), 263–269.
16. Clark, I.E., Dodson, M.W., Jiang, C., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441 (2006), 1162–1166.
17. Cookson, M.R., Hardy, J., Lewis, P.A., Genetic neuropathology of Parkinson's Disease. Int J Clin Exp Pathol 1 (2008), 217–231.
18. Decressac, M., Volakakis, N., Björklund, A., et al. NURR1 in Parkinson disease – from pathogenesis to therapeutic potential. Nat Rev Neurol 9 (2013), 629–636.
19. De Mena, L., Coto, E., Sánchez-Ferrero, E., et al. Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease. J Neural Transm 116 (2009), 1289–1293.
20. Devine, M., Ryten, M., Vodicka, M., et al. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun, 2, 2011, 440.
21. Di Fonzo, A., Dekker, M.C.J., Montagna, P., et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72 (2009), 240–245.
22. Djarmati, A., Hedrich, K., Svetel, M., et al. Heterozygous PINK1 mutations: a susceptibility factor for Parkinson disease?. Mov Disord 21 (2006), 1526–1530.
23. Doherty, K.M., Silveira-Moriyama, L., Parkkinen, L., et al. Parkin disease: a clinicopathologic entity?. JAMA Neurol 70 (2013), 571–579.
24. Domingo, A., Lee, L.V., Brüggemann, N., et al. Woman with X-linked recessive dystonia-parkinsonism: clue to the epidemiology of parkinsonism in Filipino women?. JAMA Neurol 71 (2014), 1177–1180.
25. Domingo, A., Erro, R., Lohmann, K., Novel dystonia genes: clues on disease mechanisms and the complexities of high-throughput sequencing. Mov Disord 31 (2016), 471–477.
26. Edvardson, S., Cinnamon, Y., Ta-Shma, A., et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One, 7, 2012, e36458.
27. Eggers, C., Schmidt, A., Hagenah, J., et al. Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. Neurology 74 (2010), 1798–1805.
28. Eisenberg, E., Greene, L.E., Multiple roles of auxilin and Hsc70 in clathrin-mediated endocytosis. Traffic 8 (2007), 640–646.
29. Exner, N., Treske, B., Paquet, D., et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 27 (2007), 12413–12418.
30. Fox, S.H., Lang, A.E., Motor and non-motor fluctuations. Koller, W.C., Melamed, E., (eds.) Handbook of clinical neurology, Parkinson's disease and related disorders, part II, 2007, Elsevier, Amsterdam, 159–184.
31. Freimann, K., Zschiedrich, K., Brüggemann, N., et al. Mortalin mutations are not a frequent cause of early-onset Parkinson disease. Neurobiol Aging 34 (2013), 2694.e19–2694.e20.
32. Funayama, M., Hasegawa, K., Ohta, E., et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57 (2005), 918–921.
33. Funayama, M., Li, Y., Tomiyama, H., et al. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 18 (2007), 273–275.
34. Funayama, M., Ohe, K., Amo, T., et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol 14 (2015), 274–282.
35. Gelmetti, V., Ferraris, A., Brusa, L., et al. Late onset sporadic Parkinson's disease caused by PINK1 mutations: clinical and functional study. Mov Disord 23 (2008), 881–885.
36. Goedert, M., Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2 (2001), 492–501.
37. Goldman, J.G., Goetz, C.G., History of Parkinson's disease. Koller, W.C., Melamed, E., (eds.) Handbook of clinical neurology, Parkinson's disease and related disorders, Part I, 2007, Elsevier, Amsterdam, 107–128.
38. Grimes, D.A., Han, F., Panisset, M., et al. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov Disord 21 (2006), 906–909.
39. Grünewald, A., Voges, L., Rakovic, A., et al. Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS ONE, 5, 2010, e12962.
40. Grünewald, A., Kasten, M., Ziegler, A., et al. Next-generation phenotyping using the Parkin example: time to catch up with genetics. JAMA Neurol 70 (2013), 1186–1191.
41. Harbo, H.F., Finsterer, J., Baets, J., et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur J Neurol 16 (2009), 777–785.
42. Hasegawa, K., Stoessl, A.J., Yokoyama, T., et al. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Park Relat Disord 15 (2009), 300–306.
43. Haugarvoll, K., Rademakers, R., Kachergus, J.M., et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70 (2008), 1456–1460.
44. Healy, D.G., Falchi, M., O'Sullivan, S.S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7 (2008), 583–590.
45. Hedrich, K., Hagenah, J., Djarmati, A., et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?. Arch Neurol 63 (2006), 833–838.
46. Hentati, F., Trinh, J., Thomson, C., et al. Lrrk2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. Neurology 83 (2014), 568–569.
47. Hunt, R., A system disease of the paralysis agitans type, characterized by atrophy of the motor cells of the corpus striatum: a contribution to the functions of the corpus striatum. Brain 40 (1917), 58–148.
48. Kachergus, J., Mata, I.F., Hulihan, M., et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76 (2005), 672–680.
49. Kasten, M., Klein, C., The many faces of alpha-synuclein mutations. Mov Disord 28 (2013), 697–701.
50. Kasten, M., Weichert, C., Lohmann, K., et al. Clinical and demographic characteristics of PINK1 mutation carriers—A meta-analysis. Mov Disord 25:7 (2010), 952–954.
51. Kett, L.R., Dauer, W.T., Leucine-rich repeat kinase 2 for beginners: six key questions. Cold Spring Harb Perspect Med, 2, 2012, a009407.
52. Kitada, T., Asakawa, S., Hattori, N., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998), 605–608.
53. Klein, C., Lohmann-Hedrich, K., Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol 20 (2007), 453–464.
54. Klein, C., Schlossmacher, M.G., The genetics of Parkinson disease: implications for neurological care. Nat Clin Pract Neurol 2 (2006), 136–146.
55. Klein, C., Schlossmacher, M.G., Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69 (2007), 2093–2104.
56. Klein, C., Westenberger, A., Genetics of Parkinson's disease. Cold Spring Harb Perspect Med, 2, 2012, a008888.
57. Klein, C., Ziegler, A., From GWAS to clinical utility in Parkinson's disease. Lancet 377 (2011), 613–614.
58. Klein, C., Lohmann-Hedrich, K., Rogaeva, E., et al. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 6 (2007), 652–662.
59. Köroğlu, Ç., Baysalb, L., Cetinkaya, M., et al. DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Park Relat Disord 19 (2013), 320–324.
60. Krebs, C.E., Karkheiran, S., Powell, J.C., et al. The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive parkinsonism with generalized seizures. Human Mutat 34 (2013), 1200–1207.
61. Krüger, R., Kuhn, W., Müller, T., et al. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 18 (1998), 106–108.
62. Krüger, R., Sharma, M., Reiss, O., et al. A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiol Aging 32 (2011), 548.e9–548.e18.
63. Kumar, K.R., Lohmann, K., Klein, C., Genetics of Parkinson disease and other movement disorders. Curr Opinion Neurol 25 (2012), 466–474.
64. Lautier, C., Goldwurm, S., Dürr, A., et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet 22 (2008), 822–833.
65. Le, W.D., Xu, P., Jankovic, J., et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 33 (2003), 85–89.
66. Lee, V.M.Y., Trojanowski, J.Q., Mechanisms of Parkinson's disease linked to pathological α-synuclein: new targets for drug discovery. Neuron 52 (2006), 33–38.
67. Lek, M., Karczewski, J., Minikel, E., et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536 (2016), 285–291.
68. Leroy, E., Boyer, R., Auburger, G., et al. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998), 451–452.
69. Lesage, S., Anheim, M., Condroyer, C., et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Human Mol Genet 20 (2011), 202–210.
70. Lesage, S., Condroyer, C., Klebe, S., et al. EIF4G1 in familial Parkinson's disease: pathogenic mutations or rare benign variants?. Neurobiol Aging 33 (2012), 2233.e1–2233.e5.
71. Lesage, S., Drouet, V., Majounie, E., et al. Loss of VPS13C function in autosomal-recessive parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-dependent mitophagy. Am J Hum Genet 98 (2016), 500–513.
72. Lev, N., Ickowicz, D., Barhum, Y., et al. DJ-1 protects against dopamine toxicity. J Neural Transm 116 (2009), 151–160.
73. Lill, C.M., Roehr, J.T., McQueen, M.B., et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet, 8, 2012, e1002548.
74. Lohmann, K., Klein, C., Next generation sequencing and the future of genetic diagnosis. Neurotherapeutics 11 (2014), 699–707.
75. Lohmann, E., Periquet, M., Bonifati, V., et al. How much phenotypic variation can be attributed to parkin genotype?. Ann Neurol 54 (2003), 176–185.
76. Luk, K.C., Lee, V.M.Y., Modeling Lewy pathology propagation in Parkinson's disease. Park Relat Disord 20 (2014), S85–S87.
77. MacArthur, D.G., Manolio, T.A., Dimmock, D.P., et al. Guidelines for investigating causality of sequence variants in human disease. Nature 508 (2014), 469–476.
78. Malgieri, G., Eliezer, D., Structural effects of Parkinson's disease linked DJ-1 mutations. Prot Sci 17 (2008), 855–868.
79. Malkus, K., Tsika, E., Ischiropoulos, H., Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Molecular Neurodegeneration, 4, 2009, 24.
80. Maraganore, D.M., de Andrade, M., Elbaz, A., et al. Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease. JAMA 296 (2006), 661–670.
81. Marras, C., Lang, A., Lohmann, K., et al. Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples. Neurology 78 (2012), 1016–1024.
82. Marx, F.P., Holzmann, C., Strauss, K.M., et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet 12 (2003), 1223–1231.
83. Mata, I.F., Wedemeyer, W.J., Farrer, M.J., et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29 (2006), 286–293.
84. Mata, I.F., Samli, A., Schneer, S., et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 65 (2008), 379–382.
85. Mazzulli, J.R., Xu, Y.H., Sun, Y., et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146 (2011), 37–52.
86. Mencacci, N.E., Isiaias, I.U., Reich, M.M., et al. Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137 (2014), 2480–2492.
87. Michell, A.W., Barker, R.A., Raha-Chowdhury, R., et al. A case of late onset sporadic Parkinson's disease with an A53T mutation in α-synuclein. J Neurol Neurosurg Psych 76 (2005), 596–597.
88. Miller, D.W., Hague, S.M., Clarimon, J., et al. α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62 (2004), 1835–1838.
89. Muhammad, A., Flores, I., Zhang, H., et al. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Aβ accumulation. Proc Natl Acad Sci 105 (2008), 7327–7332.
90. Nalls, M.A., Pankratz, N., Lill, C.M., et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46 (2014), 989–993.
91. Nishioka, K., Ross, O., Ishii, K., et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 24 (2009), 1811–1819.
92. Norris, E.H., Giasson, B.I., Lee, V.M.Y., α-Synuclein: normal function and role in neurodegenerative diseases. Schatten, G.P., (eds.) Current topics in developmental biology vol 60, Stem cells in development and disease, 2004, Academic Press, 17–54 ISBN: 978-0-12-153160-7.
93. Nuytemans, K., Theuns, S., Cruts, M., et al. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31 (2010), 763–780.
94. Ozelius, L., Senthil, J., Saunders-Pullman, R., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354 (2006), 424–425.
95. Paisán-Ruíz, C., Jain, S., Evans, E.W., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004), 595–600.
96. Parkkinen, L., Kauppinen, T., Pirttilä, T., α-Synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57 (2005), 82–91.
97. Perl, D.P., The neuropathology of parkinsonism. Koller, W.C., Melamed, E., (eds.) Handbook of clinical neurology, Parkinson's disease and related disorders, part I, 2007, Elsevier, Amsterdam, 205–215.
98. Polymeropoulos, M.H., Lavedan, C., Leroy, E., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2047.
99. Poulopoulos, M., Levy, O.A., Alcalay, R.N., The neuropathology of genetic Parkinson's disease. Mov Disord 27 (2012), 831–842.
100. Pramstaller, P., Schlossmacher, M., Jacques, T., et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 58 (2005), 411–422.
101. Proukakis, C., Dudzik, C.G., Brier, T., et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 80 (2013), 1062–1064.
102. Puschmann, A., Ross, O.A., Vilariño-Güell, C., et al. A Swedish family with de novo α-synuclein A53T mutation: evidence for early cortical dysfunction. Park Relat Disord 15 (2009), 627–632.
103. Quadri, M., Fang, M., Picillo, M., et al. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset parkinsonism. Hum Mutat 34 (2013), 1208–1215.
104. Rakovic, A., Grünewald, A., Kottwitz, J., et al. Mutations in PINK1 and Parkin impair ubiquitination of mitofusins in human fibroblasts. PLoS One, 6, 2011, e16746.
105. Ricciardi, L., Petrucci, S., Guidubaldi, A., et al. Phenotypic variability of PINK1 expression: 12 years’ clinical follow-up of two Italian families. Mov Disord 29:12 (2014), 1561–1566 (Epub ahead of print).
106. Ritz, B., Rhodes, S., Bordelon, Y., et al. α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS One, 7, 2012, e36199.
107. Ross, O.A., Toft, M., Whittle, A., Lrrk2 and Lewy body disease. Ann Neurol 59 (2006), 388–393.
108. Ross, O.A., Spanakib, C., Griffith, A., Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Park Relat Disord 15 (2009), 466–467.
109. Ross, O.A., Soto-Ortolaza, A.I., Heckman, M.G., et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol 10 (2011), 898–908.
110. Samaranch, L., Lorenzo-Betancor, O., Arbelo, J.M., et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 133 (2010), 1128–1142.
111. Sánchez-Danés, A., Richaud-Patin, Y., Carballo-Carbajal, I., et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 4 (2012), 380–395.
112. Saunders-Pullman, R., Stanley, K., Wang, C., et al. Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology 77 (2011), 319–324.
113. Shahed, J., Jankovic, J., Motor symptoms in Parkinson's disease. Koller, W.C., Melamed, E., (eds.) Handbook of clinical neurology, Parkinson's disease and related disorders, part I, 2007, Elsevier, Amsterdam, 329–342.
114. Sharma, M., Ioannidis, J.P.A., Aasly, J.O., et al. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet 49 (2012), 721–726.
115. Shojaee, S., Sina, F., Banihosseini, S., et al. Genome-wide linkage analysis of a parkinsonian-pyramidal syndrome pedigree by 500K SNP arrays. Am J Hum Genet 82 (2008), 1375–1384.
116. Sidransky, E., Nalls, M.A., Aasly, J.O., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361 (2009), 1651–1661.
117. Singleton, A.B., Farrer, M., Johnson, J., et al. α-Synuclein locus triplication causes Parkinson's disease. Science, 302, 2003, 841.
118. Spillantini, M.G., Schmidt, M.L., Lee, V.M., α-Synuclein in Lewy bodies. Nature 388 (1997), 839–840.
119. Stamelou, M., Quinn, N.P., Bhatia, K., “Atypical” atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy – diagnostic guide. Mov Disord 28 (2013), 1184–1199.
120. Strauss, K.M., Martins, L.M., Plun-Favreau, H., et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 14 (2005), 2099–2111.
121. Tadic, V., Kasten, M., Brüggemann, N., Dopa responsive dystonia revisited: diagnostic delay, residual signs, and nonmotor signs. Arch Neurol 69 (2012), 1558–1562.
122. Tan, E.K., Shena, H., Tan, L.C.S., et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 384 (2005), 327–329.
123. Tan, E.K., Peng, R., Wu, Y.R., et al. LRRK2 G2385R modulates age at onset in Parkinson's disease: a multi-center pooled analysis. Am J Med Genet Part B: Neuropsych Genet 150B (2009), 1022–1023.
124. Tanner, C.M., Ottman, R., Goldman, S.M., et al. Parkinson disease in twins: an etiologic study. JAMA 281 (1999), 341–346.
125. Taylor, J.P., Mata, I.F., Farrer, M.J., LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?. Trends Mol Med 12 (2006), 76–82.
126. Trinh, J., Guella, I., Farrer, M.J., Disease penetrance of late-onset parkinsonism: a meta-analysis. JAMA Neurol 71 (2014), 1535–1539.
127. Tsuang, D., Leverenz, J.B., Lopez, O.L., et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 79 (2012), 1944–1950.
128. Tsunemi, T., Krainc, D., Zn2 + dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum Mol Genet 23 (2014), 2791–2801.
129. Tuccia, A., Charlesworth, G., Sheerin, U., et al. Study of the genetic variability in a Parkinson's disease gene: EIF4G1. Neurosci Lett 518 (2012), 19–22.
130. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004), 1158–1160.
131. Vilariño-Güell, C., Wider, C., Ross, O.A., et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 89 (2011), 162–167.
132. Vilariño-Güell, C., Rajput, A., Milnerwood, A.J., DNAJC13 mutations in Parkinson disease. Hum Mol Genet 23 (2014), 1794–1801.
133. Weissbach, A., Klein, C., Hereditary dystonia and parkinsonism: two sides of the same coin?. Brain 137 (2014), 2402–2404.
134. Wider, C., Dickson, D.W., Wszolek, Z.K., Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegen Dis 7 (2010), 175–179.
135. Williams, D.R., Litvan, I., Parkinsonian syndromes. Continuum 19 (2013), 1189–1212.
136. Wilson, G.R., Sim, J.C.H., McLean, C., et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology. Am J Hum Genet 95 (2014), 729–735.
137. Winkler, S., Hagenah, J., Lincoln, S., et al. α-Synuclein and Parkinson disease susceptibility. Neurology 69 (2007), 1745–1750.
138. Wirdefeldt, K., Gatz, M., Reynolds, C.A., et al. Heritability of Parkinson disease in Swedish twins: a longitudinal study. Neurobiol Dis, 32, 2011 1923.e1-8.
139. Youle, R.J., Narendra, D.P., Mechanisms of mitophagy. Nat Rev Mol Cell Biol 12 (2011), 9–14.
140. Zanon, A., Rakovic, A., Blankenburg, H., et al. Profiling of Parkin-binding partners using tandem affinity purification. PLoS ONE, 8, 2013, e78648.
141. Zarranz, J.J., Alegre, J., Gómez-Esteban, J.C., et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55 (2004), 164–173.
142. Zimprich, A., Biskup, S., Leitner, P., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004), 601–607.
143. Zimprich, A., Benet-Pagès, A., Struhal, W., A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 89 (2011), 168–175.